Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

AstraZeneca to Build Qingdao Regional Headquarters with Rare Disease Innovation Center

publication date: Jun 23, 2022

AstraZeneca will set up its sixth China regional headquarters in Qingdao, a port city in eastern Shandong province, forming a rare disease innovation center, a life science innovation park and an industry fund. The company will also construct a manufacturing facility for Breztri, an aerosol therapy for COPD at the site. AstraZeneca’s budesonide/glycopyrronium/formoterol fumarate COPD therapy was approved for China use in 2020 and added to China’s national medical insurance list last year. The company did not disclose any financial data for the expansion. More details....

Stock Symbol: (NYSE: AZN)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
September 13-16, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022